Review of the Role of MRI Targeted Biopsy vs Systematic Biopsy in Prostate Cancer

Mukesh Harisinghani, MD, Director of the Clinical Discovery Program Center for Molecular Imaging Research at Massachusetts General Hospital, reviews recent research on the effectiveness of MRI-targeted biopsy, as well as systematic biopsy on biopsy-naive prostate cancer patients. Through the analysis of research results, he reveals that there is consistent evidence to support the conclusion that combining the two techniques creates a substantial boost in detection rates. This boost has been proven to be a shift from a 21.4% detection rate in just systematic biopsy and 23.4% in just MRI-targeted biopsy to a detection rate of 27.7% when using combined techniques on biopsy naive patients.

[robertmizek]

Great content on this channel. Thank you for posting it. It’s tragic that many big insurance companies (like the one I’m insured with) treat MRI Fusion biopsies and Saturation biopsies as “experimental” and “investigative” and deny claims for them. Many patients choose biopsies that miss the cancer leading to a false negative diagnosis. I hope that other patients like myself can get a class action lawsuit going against them once COVID19 in no longer a pandemic threat.

[chenoby]

Great content, but I didn't understand how many sistematic biopsies in association to target biopsy we should perform ?

[thomasjones]

Bottom line, if I do nothing but enjoy the rest of the time on this earth without visiting any more Doctors, I'm good.